Latest KFF Health News Stories
Out-Of-Pocket Costs Often Keep Pricey New Cholesterol Drugs Out Of Reach, Study Finds
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The company’s drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
FDA Moves To Guard Against Abuse Of ‘Orphan Drug’ Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
Facebook Live: The Prescription Drug Pricing Pipeline
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
Dying At Home In An Opioid Crisis: Hospices Grapple With Stolen Meds
As more patients receive hospice care at home, some of the powerful, addictive drugs they’re prescribed are ending up in the wrong hands.
Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
Taking A U-Turn On Benefits, Big Employers Vow To Continue Offering Health Insurance
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
Florida Law Will Let Patients Get All Their Drug Renewals At The Same Time
The new law will help people with chronic conditions that require multiple prescriptions cut down on their shuttles to the drug store and could improve adherence to their drugs.
Denial, Appeal, Approval … An Adult’s Thorny Path To Spinraza Coverage
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
Drug Puts A $750,000 ‘Price Tag On Life’
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Whichever Way ‘Repeal And Replace’ Blows, Pharma Is Due For Windfall
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Amount Of Opioids Prescribed In U.S. Has Been Falling Since 2010
Report by CDC researchers finds a steady fall in opioid use in recent years, but the rates are still three times higher than in 1999.
Alerta por nueva droga: es para neuropatías, pero la usan adictos a opioides
La gabapentina se utiliza para tratar afecciones de los nervios, pero la están usando cada vez más adictos a opioides. Es la quinta droga más recetada del país.
New On The Streets: Drug For Nerve Pain Boosts High For Opioid Abusers
Gabapentin, prescribed for epilepsy and nerve damage, is touted by federal health officials as an alternative to opioids for patients. But some are now abusing the drug.
Patients With Mental Disorders Get Half Of All Opioid Prescriptions
A study finds that nearly 19 percent of people with mental illnesses use prescription drugs, while only 5 percent of other people do.
Promises Made To Protect Preexisting Conditions Prove Hollow
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Huecos en las promesas de proteger la cobertura de condiciones preexistentes
Expertos en políticas de salud que han analizado el texto del proyecto de salud del Senado, aseguran que la legislación no siempre garantizaría la atención de personas con condiciones preexistentes.
Exclusive: White House Task Force Echoes Pharma Proposals
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
Former Pharma Reps’ New Mission: To School Docs On High Drug Costs
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
